Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Februar 2026 16:30 ET | Quelle: Profound Medical Corp.

Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...
12. Februar 2026 08:30 ET | Quelle: Profound Medical Corp.

Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is...
04. Dezember 2025 17:00 ET | Quelle: Profound Medical Corp.

Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
28. November 2025 07:45 ET | Quelle: Profound Medical Corp.

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
18. November 2025 16:15 ET | Quelle: Profound Medical Corp.

Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
11. November 2025 16:15 ET | Quelle: Profound Medical Corp.

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

Agreement creates runway for Profound’s incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East All required...
16. Oktober 2025 08:00 ET | Quelle: Profound Medical Corp.

Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
14. Oktober 2025 08:30 ET | Quelle: Profound Medical Corp.

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
07. Oktober 2025 07:45 ET | Quelle: Profound Medical Corp.

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
30. September 2025 08:00 ET | Quelle: Zenflow

Zenflow Receives FDA 510(k) Clearance for First-of-Its-Kind Single-Use Cystoscope

Zenflow, Inc. announced it has received 510(k) clearance from the US FDA for the Zenflow Spring® Scope & Camera Control Unit.

Nächste Seite